


WuXi XDC and LigaChem Biosciences expand MoU to accelerate ADC development

25 February 2025 | News

LigaChem will utilise WuXi XDC's fully integrated ADC development and manufacturing platform to support multiple ADC projects



China-based WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced the signing of an expanded Memorandum of Understanding (MoU) with South Korea-based LigaChem Biosciences, Inc., a leader in the development of innovative ADC therapies targeting cancer and other serious diseases.

This new agreement broadens the scope of the ongoing collaboration, further accelerating the development of next generation innovative ADC therapies.

Under the terms of the expanded MoU, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programmes. With WuXi XDC's cutting-edge technologies and extensive expertise, LigaChem will be well-positioned to seamlessly advance its ADC candidates from discovery through to development stages, ensuring a more streamlined and efficient process at every stage.

Furthermore, LigaChem will utilise WuXi XDC's fully integrated ADC development and manufacturing platform to support multiple ADC projects. This strategic expansion of the partnership strengthens both companies' shared mission to develop and deliver innovative ADC therapies that address critical unmet patients needs.

This expanded MoU builds on the initial collaboration between WuXi XDC and LigaChem, which began in 2021. Since then, both companies have made significant strides in advancing the innovation of ADCs and bioconjugates. This new agreement further solidifies the shared vision of advancing the next wave of innovation in the ADC field, poised to deliver meaningful benefits to patients worldwide.